FDA's DSCSA enforcement discretion ended on 27 November 2024; since then it has used formal exemptions, and all have expired except for small dispensers.
The small dispenser exemption now runs to 27 November 2027, for pharmacies with 25 or fewer full-time pharmacists and technicians as of 27 November 2026.
Small pharmacies must still deal only with authorized trading partners and quarantine and investigate suspect product, and FDA is enforcing these duties.
Until 27 November 2027, suppliers to small pharmacies run two modes: serialized EPCIS for most customers, current methods for qualifying small dispensers.
Most US trading partners planned for 27 November 2026 as the last DSCSA deadline, and on 6 August 2026 FDA moved it for small pharmacies to 27 November 2027. The change matters because the final phase of the Drug Supply Chain Security Act (DSCSA) depends on every link exchanging accurate, package-level electronic data. In June 2024, only 4% of wholesale distributors surveyed by the Partnership for DSCSA Governance (PDG) routinely received complete serialized data from at least 80% of their suppliers; by June 2025, 64% did.
That progress is why FDA ended its broad relief for manufacturers, wholesale distributors and larger pharmacies in 2025, and why the remaining gap now sits with small dispensers. For the wider context on serialization rules across the US, EU and Asia, see our guide to pharmaceutical traceability. Zelthy, an AI-native Platform-as-a-Service built on the open-source Zango framework, supports pharma teams with serialized tracking, GS1 data and DSCSA traceability workflows across its Traceability and Supply Chain vertical.
This post explains the difference between enforcement discretion and exemptions, gives a single "who must do what by when" table as of November 2026, lists what still applies during the small dispenser exemption, and sets out practical steps for each trading partner type.
Enforcement discretion vs DSCSA exemptions: what is the difference?
Enforcement discretion is FDA choosing not to act against a requirement that is already in force. A DSCSA exemption is FDA formally lifting specific requirements for defined parties under its statutory authority in section 582(a)(3) of the FD&C Act. From 2023 to 2024 FDA used the first tool; since 27 November 2024 it has used the second.
The stabilization period (August 2023 to 27 November 2024)
The enhanced drug distribution security (EDDS) requirements in section 582(g)(1) took effect on 27 November 2023. In August 2023 FDA published compliance policies for the 582(g)(1) requirements and announced a one-year stabilization period "until November 27, 2024". The law did not change. FDA simply signalled it would not enforce the electronic, interoperable, package-level tracing requirements during that year, and warned that the period "should not be viewed as providing, a justification for delaying efforts to comply with the DSCSA."
Exemptions under section 582(a)(3)
When the stabilization period ended, FDA switched to written exemptions. The agency's waivers, exceptions and exemptions page describes three distinct tools:
Waiver: requested by an authorized trading partner when a requirement would cause undue economic hardship, or for emergency medical reasons.
Exception: requested by a manufacturer or repackager when a container is too small to carry the product identifier.
Exemption: for other products or transactions, which FDA can grant on request or issue itself, as it did for whole classes of trading partners.
DSCSA exemptions by trading partner: who must do what by when (as of November 2026)
As of 17 November 2026, every DSCSA exemption for manufacturers, repackagers, wholesale distributors and dispensers with 26 or more full-time pharmacists and technicians has expired. Only qualifying small dispensers remain exempt from the electronic tracing requirements, and only until 27 November 2027.
FDA's October 2024 exemption letter staggered the end dates by sector. It covered trading partners that had completed data connections with their immediate partners by 27 November 2024, or had documented good-faith efforts to do so. Those relying on it did not file anything with the FDA, but were expected to tell their trading partners.
Trading partner
Exempted requirements
Exemption end date
Status (Nov 2026)
FDA source
All trading partners (stabilization period)
Enforcement of 582(g)(1) electronic, package-level tracing
27 Nov 2024
Ended
[FDA statement, Aug 2023](https://www.fda.gov/drugs/drug-alerts-and-statements/dscsa-compliance-policies-establish-1-year-stabilization-period-implementing-electronic-systems)
Manufacturers and repackagers (eligible)
582(g)(1)(A) to (F)
27 May 2025
Expired: full compliance expected
[FDA letter, 9 Oct 2024](https://www.fda.gov/media/182584/download)
Wholesale distributors (eligible)
582(g)(1)(A) to (F) and 582(c)(4)(D) saleable returns verification
27 Aug 2025
Expired: full compliance expected
[FDA letter, 9 Oct 2024](https://www.fda.gov/media/182584/download)
Dispensers with 26+ full-time pharmacists and technicians (eligible)
582(g)(1)(A) to (F) and 582(d)(4) suspect product verification provisions
27 Nov 2025
Expired: full compliance expected
[FDA letter, 9 Oct 2024](https://www.fda.gov/media/182584/download)
Small dispensers (25 or fewer), original exemption
582(g)(1)(A) to (F) and 582(d)(4) suspect product verification provisions
Small dispensers (25 or fewer, counted as of 27 Nov 2026) and their trading partners, where noted
Same provisions; partners may use current methods for these transactions and saleable returns
27 Nov 2027
Active
[FDA letter, 6 Aug 2026](https://www.fda.gov/media/194424/download)
DSCSA exemption status by trading partner type, as of November 2026
The 2026 extension for small dispensers
The 6 August 2026 letter extends the small dispenser exemption by one year, to 27 November 2027. A small dispenser is one whose owning corporate entity has 25 or fewer full-time employees who are licensed pharmacists or qualified pharmacy technicians, using the IRS full-time definition (30 hours a week or 130 hours a month). The headcount is taken as of 27 November 2026, not 2024, so a pharmacy group that has grown past 25 since 2024 loses the exemption on 27 November 2026.
FDA's stated reason is that the statutory small dispenser assessment under section 582(g)(3) is not finished. The agency's exemptions page says the extra year gives it time to complete the assessment, publish the report for public comment and hold a public meeting. FDA encouraged small dispensers to complete its assessment survey by 22 September 2026.
Exemption end dates by trading partner. Four have closed; the small dispenser exemption runs to 27 November 2027.
What DSCSA requirements still apply during the small dispenser exemption?
Every section 582 requirement outside the listed electronic tracing and verification provisions still applies to small dispensers today. FDA's August 2026 letter states that the exemptions do not cover other section 582 requirements, and that the enhanced requirements "remain in effect" for every trading partner that is not a small business dispenser.
In practice, small pharmacies still need to:
Buy from and sell to authorized trading partners only.
Receive and keep transaction information and statements using their current methods.
Perform the verification steps in section 582(d)(4) that the letter does not exempt, including quarantining and investigating suspect product.
Respond to recall and suspect product requests, which they may do using current methods during the exemption.
FDA is enforcing these duties. On 1 April 2026 it issued a warning letter to Pure Indulgence Aesthetics, a Texas medical spa it treated as a dispenser, citing failure to show it transacted only with authorized trading partners (section 582(d)(3)) and product lacking a required product identifier (section 582(d)(2)).
DSCSA compliance actions by trading partner before and after 27 November 2026
Manufacturers, distributors and large dispensers should treat the electronic tracing requirements as fully enforceable and focus on data quality and exception speed. Small dispensers should confirm eligibility now and use the extra year to connect. Every supplier to small pharmacies should plan to support two operating modes until 27 November 2027.
Manufacturers and repackagers
Package-level EPCIS data is now a condition of moving product. The remaining risk is exceptions: at a June 2025 FDA and PDG town hall, distributors said resolving data discrepancies was "oftentimes ranging from two to seven days". Track exception volume, root cause and time to resolution by customer.
Wholesale distributors
The August 2026 letter lets trading partners of small dispensers keep using current methods for those transactions, including accepting saleable returns. In practice, a distributor serving independent pharmacies will typically run serialized EPCIS exchange for most customers and current methods for qualifying small ones. At the PDG town hall, distributors warned that running "dual systems" for lot-level and package-level tracing to accommodate FDA-granted exemptions is technically difficult and raises costs. Keep an auditable record of which customers rely on the exemption and on what basis.
Running two DSCSA modes until 2027?
Zelthy lets supply chain teams configure an exemption reliance register, customer-level tracing mode and an exception queue as workflows, alongside existing serialization and EPCIS systems.
Dispensers with 26 or more full-time pharmacists and technicians
These pharmacies have been out of exemption since 27 November 2025. Confirm receiving workflows capture product identifiers at package level, that saleable returns link back to original transaction data, and that suspect product verification runs at package level.
Small dispensers
Count licensed pharmacists and qualified technicians across the whole owning entity as of 27 November 2026, and document the count. Tell wholesalers you rely on the exemption. Use 2027 to complete data connections; FDA's letter "strongly urges small business dispensers to continue their efforts."
How to file a DSCSA waiver request
A trading partner that does not qualify and cannot comply can request a waiver, exception or exemption. FDA's exemptions page notes that requests it has received included steps already taken, why more time is needed, the implementation plan and full-time employee count. CDER products go through the CDER NextGen portal; CBER products through the Electronic Submissions Gateway or the CBER mailbox. A pending request does not pause obligations: FDA "expects the trading partner to continue their efforts to meet the requirements until FDA has approved or denied the request."
Check
Who
Done when
Headcount documented as of 27 Nov 2026
Small dispensers
Signed record of full-time pharmacists and technicians across the owning entity
Exemption reliance register
Distributors, manufacturers
List of customers relying on the exemption, with date and evidence
Exception KPIs
All non-exempt partners
Volume, root cause and time to resolution reported monthly
Saleable returns linkage
Distributors, large dispensers
Returns matched to original transaction data before resale
Authorized trading partner checks
Everyone
Licence verification on file for every partner
DSCSA readiness checklist, November 2026
Until 27 November 2027, suppliers to small pharmacies run two modes: serialized EPCIS for most customers, current methods for qualifying small dispensers.
Teams can configure an exemption reliance register, customer-level tracing mode and an exception queue as workflows on Zelthy, alongside existing serialization and EPCIS systems.
Proof point: supply chain programs deployed on Zelthy
Zelthy works at the data, workflow, aggregation, permissions and reporting layer. It does not print codes or sell serialization hardware. A blockchain-based supply chain platform deployed on Zelthy recorded 15% fewer stockouts and 25% faster inventory turnover. That result came from a supply chain visibility program, not a DSCSA-specific deployment, so treat it as evidence that shared, permissioned supply chain data changes operating outcomes, not as a compliance metric. More broadly, Zelthy has supported 300+ applications deployed across 12+ countries, for organizations including Roche, Pfizer, AstraZeneca and DKSH. For DSCSA, the same pattern applies: one governed record of trading partner status, exemption reliance and exceptions, shared by quality, supply chain and customer teams. For how this fits a broader programme, see the executive guide to traceability implementation.
This article summarizes FDA documents as of 17 November 2026 and is not legal advice. Confirm your obligations with regulatory counsel.
Frequently asked questions
Was the DSCSA small dispenser exemption extended to 2027?
Yes. On 6 August 2026 FDA extended the small dispenser exemption from 27 November 2026 to 27 November 2027. It covers dispensers whose owning entity has 25 or fewer full-time licensed pharmacists and qualified pharmacy technicians, counted as of 27 November 2026.
Do I need to apply to FDA to use a DSCSA exemption?
No. Qualifying small dispensers and their trading partners do not need to submit anything to FDA. FDA encourages them to tell their trading partners they are relying on the exemption, and keeping a documented headcount is good practice.
Is FDA still using enforcement discretion for DSCSA electronic tracing?
No. FDA's enforcement discretion, the stabilization period, ended on 27 November 2024. Since then FDA has used formal exemptions under section 582(a)(3), and all of them have expired except the small dispenser exemption.
What DSCSA rules still apply to small pharmacies during the exemption?
All section 582 requirements outside the listed electronic tracing and verification provisions still apply. That includes dealing only with authorized trading partners, receiving transaction information by current methods, and quarantining and investigating suspect product.
Can a manufacturer or distributor still get more time under DSCSA?
Only by requesting a waiver, exception or exemption from FDA, with a detailed justification and implementation plan. A pending request does not pause obligations, and FDA expects work to continue until it approves or denies the request.
If your team is planning DSCSA exception handling, partner status tracking or dual-mode operations through 2027, book a demo with Zelthy.
Related Solution
Planning DSCSA operations through 2027?
Zelthy is pharma's traceability platform — one governed record of trading partner status, exemption reliance and exceptions, shared by quality, supply chain and customer teams. It works at the data, workflow and reporting layer alongside your serialization systems, and has supported 300+ applications across 12+ countries for organizations including Roche, Pfizer, AstraZeneca and DKSH.